Communiqués Shield Therapeutics plc

Actions

Marché Fermé - London S.E. Autres places de cotation 17:35:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,6 ^GBX	0,00 %		-3,03 %	-76,12 %

03/07	RÉSULTATS ET TRANSACTIONS : ActiveOps fait des bénéfices ; Contango obtient un investissement	AN
03/07	Rudolf Widmann rejoint le conseil d'administration de Shield Therapeutics plc en tant que directeur non exécutif	CI

Shield Therapeutics : Results of 2024 Annual General Meeting	20/06	PU
Hardman & Co: Shield Therapeutics (STX): Cash management is key	23/05	EQ
Shield Therapeutics : 2023 Annual Report and Accounts	10/05	PU
Shield Therapeutics : Notice of Annual General Meeting 2024	10/05	PU
Shield Therapeutics : Letter to Shareholders 2024	10/05	PU
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team	15/11	EQ
Shield to Present Abstract at 26th Annual Women's Healthcare Conference 2023 on Accrufer	23/10/23	AQ
Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst	05/10/23	AQ
Shield Therapeutics "couldn't be more pleased" with Viatris collaboration	05/10/23	AQ
Shield Therapeutics : Launch Announcement	28/09/23	PU
Proactive Research Analyst says Shield Therapeutics' commercialisation drive "going well"	01/08/23	AQ
Shield Therapeutics "really starting to fire on all cylinders"	25/07/23	AQ
Shield Therapeutics : Notice of Annual General Meeting 2023	19/05/23	PU
Shield Therapeutics : 2022 Annual Report and Accounts	19/05/23	PU
Shield Therapeutics : Letter to Shareholders	19/05/23	PU
Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc	09/05/23	PR
Form 8.3 - Shield Therapeutics plc	09/05/23	AQ
Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc	09/05/23	PR
Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc	05/05/23	PR
Shield Therapeutics : Rule 2.11 Letter to Employees	04/05/23	PU

Aucun résultat pour cette recherche